1. Menglan Luo, Qian Wu, Yueyue Yang, Lin Sun, Xiajuan Huan, Changqing Tian, Bing Xiong, Zehong Miao, Yingqing Wang*, Danqi Chen*. Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities. European Journal of Medicinal Chemistry 2022, 239, 114519.
2. Qi Wang, Bixi Tang, Dandan Sun, Ying Dong, Yinchun Ji, Huanyu Shi, Liwei Zhou, Yueyue Yang, Menglan Luo, Qian Tan, Lin Chen, Yue Dong, Cong Li, Rongrong Xie, Yi Zang, Jingkang Shen, Bing Xiong, Jia Li*, Danqi Chen*. Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis. Acta Pharmaceutica Sinica B 2022, 12 (4), 1943-1962.
3. Dong Y, Tang BX, Wang Q, Zhou LW, Li C, Zhang X, Sun DD, Sun X, Zhang XM, Xiong B, Li J, Shi H*, Chen DQ*, Zang Y*. Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis. Acta Pharmacologica Sinica 2022, 43, 1769-1779.
4. Wu Q#, Chen DQ#, Sun L, Huan XJ, Bao XB, Tian CQ, Hu J, Lv KK, Wang YQ*, Xiong B*, Miao ZH.* Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1. Biochemical Pharmacology 2021, 185, 114435.
5. Yang B, Wu Q, Huan X, Wang Y, Sun Y, Yang Y, Liu T, Wang X, Chen L, Xiong B, Zhao D*, Miao Z*, Chen D*. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 2021, 33, 127749.